Diligent Announces Pending Change to Board WELLINGTON, New

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Diligent Announces Pending Change to Board

WELLINGTON, New Zealand, Aug. 5, 2014 (GLOBE NEWSWIRE) -- Diligent Board Member Services, Inc. ("Diligent" or the "Company") (NZX:DIL) today announced that Mark Weldon intends to resign from the Board of Diligent as a consequence of accepting the position of Chief Executive of Mediaworks New Zealand. Given the nature of his new role as Chief Executive, combined with the fact Diligent is headquartered in New York, it will not be feasible for Mark to remain a Director of Diligent.

Mark has agreed to remain on Diligent's Board until such time that the Company finds a replacement so that the Company can continue to meet its requirement to have two resident New Zealand directors under the NZX Listing Rules. Diligent is appreciative of Mark's flexibility to work through the timing of his resignation with the Diligent Board.

Mr. David Liptak, Chairman of the Board, said: "We would like to thank Mark for his contribution to the Diligent Board and continued support whilst we go through the process of appointing another New Zealand director. We wish him all the very best in his new role at Mediaworks New Zealand."

Mr. Weldon commented: "Diligent is an outstanding technology company that is regaining momentum, and has a bright future. I have valued my time with the company, and wish it all the best for future success."

Safe Harbor Statement

Statements made in this press release that state Diligent's or management's intentions, beliefs, expectations, or predictions for the future are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Readers are cautioned that these statements are only predictions and may differ materially from actual future events or results. All forward looking-statements are only as of the date of this press release and Diligent undertakes no obligation to update or revise them. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause Diligent's actual results to differ materially from those projected in such forward-looking statements. For example, if we do not successfully develop or introduce new product offerings, or enhancements to our existing Diligent Boardbooks offerings, or keep pace with technological changes that impact the use of our product offerings, or suffer security breaches or service interruptions, we may lose existing customers or fail to attract new customers and our financial performance and revenue growth may suffer. Factors which could cause our actual results to differ materially from those projected in forward-looking statements include, without limitation, economic, competitive, regulatory and technological factors affecting Diligent Board Member Services, Inc.'s operations, markets, products, services and other factors set forth in the Company's Risk Factors included in its Annual Report on Form 10-K/A filed with the SEC on May 20, 2014.

Investor inquiries: Sonya Joyce Ph: + 64 4 894 6912 Media inquiries: Geoff Senescall Ph: + 64 21 481 234

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 313

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Updated Category News Views 193

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 128

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 130

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 258

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 224

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 332

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Updated Category News Views 134

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 541

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Tennessee's Bold Lung Cancer Trial Signals Innovation

Updated Category News Views 161

The Heartbeat of Innovation in Cancer Therapy Who would've thought Tennessee would be at the forefront of a global push against lung cancer? Sure, there's Nashville's music scene, but it's the researchers at Tennessee Oncology who are grooving to a different beat—one that might just set the rhythm for advanced cancer therapies worldwide. Yeah, it's a trial, but not just...

Continue Reading

Top 5 Most Recently Viewed Articles

Oportun Prepares for Upcoming Financial Results Announcement

Updated Category News Views 74

Upcoming Financial Results Announcement Oportun (NASDAQ: OPRT), a leader in mission-driven financial services, is gearing up for its anticipated release of third-quarter financial results. The announcement is set for Tuesday, after market hours, marking an important milestone for the company. Financial Results and Investor Insights The conference call and earnings webcast...

Continue Reading
Latest Patent Grant Marks a Milestone for Propanc Biopharma

Updated Category News Views 114

Propanc Biopharma Achieves a New Patent Milestone Propanc Biopharma, Inc. (NASDAQ: PPCB), a pioneer in biopharmaceutical innovation, has recently received a certificate of grant for its patent regarding a "proenzyme composition" from the US Patent & Trademark Office. This advancement follows the company's commitment to developing groundbreaking cancer treatments aimed at...

Continue Reading
How $100 Invested in Dell Technologies Grows Over 5 Years

Updated Category News Views 172

Understanding the Growth of Dell Technologies Dell Technologies has demonstrated remarkable resilience in the market, presenting an annualized return of 38.53% over the past five years, which is 24.26% higher than the market average. As of now, the company's market capitalization stands impressively at $73.08 billion. This strong performance reflects Dell's innovative...

Continue Reading
Osa Rooftop Lounge Opens: A Culinary Escape in Pasadena

Updated Category News Views 267

Osa Rooftop Lounge: A Culinary Haven in Pasadena Osa, a remarkable rooftop restaurant located atop the new AC Hotel Pasadena, is set to launch soon, inviting diners into a unique experience that melds delicious food, awe-inspiring views, and nature-inspired design. Nestled in Pasadena's vibrant Playhouse Village, Osa offers guests an exciting new dining destination likely...

Continue Reading
AnaptysBio: Engaging Investors at Key Conferences This November

Updated Category News Views 148

AnaptysBio's Commitment to Engagement at Investor Conferences AnaptysBio, Inc. (Nasdaq: ANAB), a pivotal player in the biotechnology sector, is dedicated to advancing immunology therapeutics aimed at treating autoimmune and inflammatory diseases. Recently, the company shared that its president and CEO, Daniel Faga, along with other senior executives, will take part in...

Continue Reading